Physician profile
Osama W Amro
NPI 1154642643
$395,036.89
in general payments reported to CMS, 2019-2025
17 companies · $100K in 2025
The $100K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $29K · 2021: $67K · 2022: $33K · 2023: $70K · 2024: $25K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Consulting Fee: $57K · Travel and Lodging: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,400 · Food and Beverage: $3,913 · Education: $6.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,845.50 |
| Consulting Fee | $56,960.00 |
| Travel and Lodging | $14,909.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,400.00 |
| Food and Beverage | $3,913.14 |
| Education | $6.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $328,004.30 | 2019-2025 | Jynarque, Voyxact, Tolvaptan |
| Novartis Pharmaceuticals Corporation | $26,556.57 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16,829.90 | 2022-2025 | |
| Travere Therapeutics, INC. | $12,489.27 | 2023-2025 | Filspari |
| Genzyme Corporation | $3,923.00 | 2020 | |
| Aurinia Pharma U.S., INC. | $2,868.56 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $2,632.57 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $516.67 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $364.03 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $248.74 | 2022-2023 | |
| Baxter Healthcare | $165.20 | 2024 | Renal - Chronic |
| Vifor Pharma, INC. | $158.60 | 2022 | |
| Mallinckrodt Hospital Products INC. | $137.63 | 2024 | Terlivaz |
| Vantive US Healthcare LLC | $122.37 | 2025 | Renal - Pd |
| Alnylam Pharmaceuticals INC. | $19.48 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osama Amro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.